- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
- Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
- Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
- Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
- Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
- Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
- First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
More ▼
Key statistics
As of last trade Quest Diagnostics Inc (DGX:NYQ) traded at 135.47, -8.85% below its 52-week high of 148.62, set on Apr 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 136.00 |
---|---|
High | 136.54 |
Low | 134.95 |
Bid | 135.37 |
Offer | 135.47 |
Previous close | 136.70 |
Average volume | 1.11m |
---|---|
Shares outstanding | 111.06m |
Free float | 110.64m |
P/E (TTM) | 18.40 |
Market cap | 15.18bn USD |
EPS (TTM) | 7.43 USD |
Annual div (ADY) | 3.00 USD |
---|---|
Annual div yield (ADY) | 2.19% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Data delayed at least 15 minutes, as of Apr 24 2024 15:26 BST.
More ▼